Treatment of chronic hepatitis C Genotype 1 (G1) infection with boceprevir (Victrelis®) in the German real-life setting: First results for treatment-naïve patients from the Novus…
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthöft, A Herrmann, M Hoesl, U Naumann, T Dahhan, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2013 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: Triple therapy with the HCV protease inhibitor boceprevir (Victrelis®) combined with pegylated interferons (PegIFN) and ribavirin (RBV) has recently been approved as new standard of care for patients (pts) with chronic HCV genotype 1 (G1) infection. As a consequent next step we conducted a non-interventional observational study (NOVUS) to investigate the efficacy and safety of this novel and more complex therapeutic approach in the German real-life setting. Methods: From April 2012 until March 2013, 307 pts with G1 infection were recruited in the ongoing NOVUS study by 85 practices and hospital ambulances…
